DAX25.117 +0,5%Est506.106 +1,2%MSCI World4.343 -0,1%Top 10 Crypto8,5300 -8,5%Nas27.144 +0,2%Bitcoin57.634 -6,0%Euro1,1639 ±0,0%Öl95,51 +0,3%Gold4.499 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
SAP 716460 NVIDIA 918422 Infineon 623100 Rheinmetall 703000 Siemens Energy ENER6Y Microsoft 870747 Micron Technology 869020 Bayer BAY001 Münchener Rückversicherungs-Gesellschaft 843002 Deutsche Telekom 555750 Amazon 906866 RENK RENK73 Lufthansa 823212 NEL ASA A0B733 ServiceNow A1JX4P
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nahostkonflikt im Blick: DAX letztlich mit Gewinnen -- Anthropic steuert wohl auf IPO zu -- Victoria's Secret, Fulcrum, Marvell, Micron, Abivax, Super Micro, Bayer, DroneShield im Fokus
Top News
JETZT LIVE: Die UMBRELLA-Strategie einfach erklärt - so funktioniert das Hypervation-Prinzip JETZT LIVE: Die UMBRELLA-Strategie einfach erklärt - so funktioniert das Hypervation-Prinzip
Rückenwind für heiß erwartete SpaceX-Aktie: Früher NVIDIA-Befürworter setzt auf die "Space Frontier" der KI Rückenwind für heiß erwartete SpaceX-Aktie: Früher NVIDIA-Befürworter setzt auf die "Space Frontier" der KI
Suche...
Jetzt kostenlos
bei finanzen.net anmelden
Watchlists & Musterdepots Tools & integriertes Trading Newsletter, Trading-Desk uvm.
Schon einen Account? Anmelden
Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

IDEAYA Biosciences Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
24,08 EUR -0,82 EUR -3,29 %
STU
28,04 USD -0,90 USD -3,11 %
BTT
finanzen.net zero
IDEAYA Biosciences jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.2,22 Mrd. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PJPB

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS45166A1025

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIDYA

IDEAYA Biosciences Aktien News

DatumMeistgelesen
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
PR NewswireIDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
PR NewswireIDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
PR NewswireIDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
PR Newswire/C O R R E C T I O N -- IDEAYA Biosciences, Inc./
PR NewswireIDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma
PR NewswireIDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
PR NewswireIDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
PR NewswireIDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
PR NewswireIDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
PR NewswireIDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event
PR NewswireIDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
PR NewswireIDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update
PR NewswireIDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Leth...
PR NewswireIDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma
PR NewswireIDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma
PR NewswireIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PR NewswireIDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer
PR NewswireIDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tu...
PR NewswireIDEAYA Announces Phase 1 Expansion and Preliminary Clinical Proof-of-Concept for Potential First-in-Class PARG Inhibitor IDE161 in HRD Solid Tumors
PR NewswireIDEAYA Biosciences to Participate in Upcoming September 2023 Investor Relations Events
PR NewswireIDEAYA Biosciences Announces Clearance of IND Application for Pol Theta Helicase Development Candidate GSK101 (IDE705)
PR NewswireIDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma
PR NewswireIDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

IDEAYA Biosciences News

IDEAYA Biosciences News: auf dieser Seite finden Sie alle IDEAYA Biosciences News und Nachrichten zur IDEAYA Biosciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch IDEAYA Biosciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um IDEAYA Biosciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.